financetom
Business
financetom
/
Business
/
First Busey Q2 Adjusted Earnings Fall, Revenue Rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
First Busey Q2 Adjusted Earnings Fall, Revenue Rises
Jul 23, 2024 3:21 PM

05:58 PM EDT, 07/23/2024 (MT Newswires) -- First Busey ( BUSE ) reported Q2 adjusted earnings late Tuesday of $0.50 per diluted share, down from $0.52 a year earlier.

Analysts polled by Capital IQ expected $0.49.

Revenue, expressed as the sum of net interest and total noninterest income, for the quarter ended June 30 was $116.2 million, up from $106.7 million a year earlier.

Four analysts surveyed by Capital IQ expected $115.4 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intellistake Says Powerbank Participating as Beta Partner in IntelliScope AI Agent Development
Intellistake Says Powerbank Participating as Beta Partner in IntelliScope AI Agent Development
Sep 24, 2025
07:55 AM EDT, 09/24/2025 (MT Newswires) -- Intellistake Technologies ( ISTKF ) said Wednesday it is developing IntelliScope, its enterprise Artificial Intelligence suite, with Nasdaq-listed Powerbank ( SUUN ) participating as a closed beta partner. Powerbank ( SUUN ), a diversified energy company, will provide long-term testing and feedback to help refine IntelliScope's first enterprise-facing agent. The IntelliScope suite is...
Exxon Mobil Eyes Billions Lost In Russia As Talks With Rosneft Take Shape
Exxon Mobil Eyes Billions Lost In Russia As Talks With Rosneft Take Shape
Sep 24, 2025
Exxon Mobil Corp. ( XOM ) has reportedly entered into a preliminary, non-binding arrangement with Russia’s Rosneft to explore avenues for recovering billions lost after its withdrawal from Russian operations in 2022. The deal, signed in late August or early September, represents the first tangible framework for Exxon to potentially claw back the $4.6 billion write-down tied to its exit,...
Cidara Says Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September
Cidara Says Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September
Sep 24, 2025
07:55 AM EDT, 09/24/2025 (MT Newswires) -- Cidara Therapeutics ( CDTX ) said Wednesday it will start enrolling patients for a phase 3 trial of CD388 by the end of September following its end-of-phase 2 meeting with the US Food and Drug Administration. The company said it is accelerating and expanding its development plan, seeking biologics license application approval based...
Acadia Pharmaceuticals' ACP-101 for Hyperphagia in Prader-Willi Syndrome Fails to Meet Primary Endpoint in Phase 3 Trial
Acadia Pharmaceuticals' ACP-101 for Hyperphagia in Prader-Willi Syndrome Fails to Meet Primary Endpoint in Phase 3 Trial
Sep 24, 2025
07:54 AM EDT, 09/24/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) said Wednesday its ACP-101, or intranasal carbetocin, therapy candidate for patients with hyperphagia in Prader-Willi syndrome did not meet its primary efficacy endpoint in a phase 3 trial. The therapy candidate failed to demonstrate a 'statistically significant improvement over placebo' from baseline to week 12. Acadia plans to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved